Total Neoadjuvant Therapy Significantly Increases Complete Clinical Response.

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Total neoadjuvant therapy (TNT) involves administering both neoadjuvant chemotherapy and chemoradiotherapy before surgery for rectal cancer.
• Standard neoadjuvant chemoradiotherapy (nCRT) is a common treatment modality for locally advanced rectal cancer.
• Evaluating the comparative outcomes of TNT versus standard nCRT is crucial for optimizing rectal cancer treatment strategies.

Discussion:

• The retrospective analysis indicates that TNT leads to a significantly higher rate of complete clinical response (58.1%) compared to standard nCRT (14.8%).
• While overall survival and distant metastasis-free survival were comparable between the groups, TNT demonstrated a marked increase in proctectomy-free survival (44% vs. 6%).
• Organ preservation rates were substantially higher in the TNT group (86.1% of complete clinical responders) compared to the standard nCRT group (37.3% of complete clinical responders).

Key Insights:

• Total neoadjuvant therapy significantly enhances complete clinical response in rectal cancer patients.
• TNT facilitates a greater opportunity for organ preservation, a critical factor for patient quality of life.
• The study did not find significant differences in 3-year overall survival or distant metastasis-free survival between TNT and standard nCRT.

Outlook:

• Further prospective studies with longer follow-up periods are warranted to confirm these findings and establish TNT as a standard of care.
• Investigating the optimal sequencing and combination of agents within the TNT paradigm may further improve outcomes.
• The findings support the consideration of TNT for patients with locally advanced rectal cancer, particularly those prioritizing organ preservation.